2024 Q1 Form 10-K Financial Statement

#000095017024018766 Filed on February 22, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $50.79M $55.60M $232.3M
YoY Change 8.24% -69.87% -67.86%
Cost Of Revenue $10.97M $8.689M $50.17M
YoY Change -25.46% -88.79% -80.86%
Gross Profit $39.82M $46.91M $182.1M
YoY Change 23.63% -56.16% -60.45%
Gross Profit Margin 78.41% 84.37% 78.4%
Selling, General & Admin $44.07M $39.79M $152.9M
YoY Change 20.58% 30.98% 16.39%
% of Gross Profit 110.65% 84.83% 83.98%
Research & Development $13.53M $14.12M $54.89M
YoY Change -0.57% 9.84% 17.78%
% of Gross Profit 33.97% 30.1% 30.14%
Depreciation & Amortization $1.124M $1.142M $4.342M
YoY Change 10.96% 36.44% 13.9%
% of Gross Profit 2.82% 2.43% 2.38%
Operating Expenses $57.59M $53.91M $207.8M
YoY Change 14.85% 24.69% 16.75%
Operating Profit -$17.77M -$7.005M -$37.03M
YoY Change -41.26% -110.99% -113.06%
Interest Expense $1.695M $7.864M $6.757M
YoY Change 0.53% 197.88% 0.37%
% of Operating Profit
Other Income/Expense, Net $101.0K $1.623M -$152.0K
YoY Change 339.13% -26.19% -236.94%
Pretax Income -$11.50M $996.0K -$4.367M
YoY Change -51.52% -98.53% -101.48%
Income Tax -$2.800M $777.0K $2.022M
% Of Pretax Income 78.01%
Net Earnings -$8.721M $219.0K -$6.389M
YoY Change -64.16% -99.68% -102.18%
Net Earnings / Revenue -17.17% 0.39% -2.75%
Basic Earnings Per Share -$0.07 -$0.05
Diluted Earnings Per Share -$0.07 $0.00 -$0.05
COMMON SHARES
Basic Shares Outstanding 130.6M 129.3M 128.7M
Diluted Shares Outstanding 130.2M 128.7M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $723.5M $742.3M $742.3M
YoY Change 10.98% 18.88% 18.88%
Cash & Equivalents $132.0M $150.3M $150.3M
Short-Term Investments $591.5M $592.0M $592.0M
Other Short-Term Assets $19.79M $19.00M $19.00M
YoY Change 26.64% -77.82% -77.82%
Inventory $61.81M $53.29M $53.29M
Prepaid Expenses
Receivables $44.16M $40.61M $40.61M
Other Receivables $1.993M $3.926M $3.926M
Total Short-Term Assets $851.3M $859.1M $859.1M
YoY Change 2.55% -6.31% -6.31%
LONG-TERM ASSETS
Property, Plant & Equipment $36.41M $37.30M $61.58M
YoY Change -4.58% -0.8% -2.77%
Goodwill $2.022M $2.067M
YoY Change -0.79% 3.04%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $73.45M $74.33M $74.33M
YoY Change -0.66% 2144.79% 2012.71%
Total Long-Term Assets $135.3M $138.0M $138.0M
YoY Change -3.22% 100.36% 100.36%
TOTAL ASSETS
Total Short-Term Assets $851.3M $859.1M $859.1M
Total Long-Term Assets $135.3M $138.0M $138.0M
Total Assets $986.6M $997.1M $997.1M
YoY Change 1.72% 1.14% 1.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.431M $5.245M $5.245M
YoY Change -66.68% 63.34% 63.34%
Accrued Expenses $45.84M $49.45M $56.93M
YoY Change 64.7% 60.97% -61.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $56.00M $62.20M $62.20M
YoY Change -38.81% -58.56% -58.56%
LONG-TERM LIABILITIES
Long-Term Debt $223.0M $222.7M $222.7M
YoY Change 0.51% 0.51% 0.51%
Other Long-Term Liabilities $203.0K $74.00K $90.13M
YoY Change -42.33% -80.73% 171.6%
Total Long-Term Liabilities $203.0K $74.00K $312.8M
YoY Change -42.33% -80.73% 22.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $56.00M $62.20M $62.20M
Total Long-Term Liabilities $203.0K $74.00K $312.8M
Total Liabilities $368.1M $375.0M $375.0M
YoY Change -9.38% -7.36% -7.36%
SHAREHOLDERS EQUITY
Retained Earnings -$939.3M -$930.6M
YoY Change -0.97% 0.69%
Common Stock $1.562B $1.555B
YoY Change 3.01% 2.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $618.5M $622.1M $622.1M
YoY Change
Total Liabilities & Shareholders Equity $986.6M $997.1M $997.1M
YoY Change 1.72% 1.14% 1.14%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$8.721M $219.0K -$6.389M
YoY Change -64.16% -99.68% -102.18%
Depreciation, Depletion And Amortization $1.124M $1.142M $4.342M
YoY Change 10.96% 36.44% 13.9%
Cash From Operating Activities -$16.68M $13.76M $100.6M
YoY Change -160.38% -60.62% 60.35%
INVESTING ACTIVITIES
Capital Expenditures $749.0K $1.704M $4.104M
YoY Change -41.62% 7.37% -42.51%
Acquisitions
YoY Change
Other Investing Activities $3.580M -$18.52M -$149.8M
YoY Change -107.01% -40.97% -51.49%
Cash From Investing Activities $2.831M -$20.23M -$153.9M
YoY Change -105.41% -38.64% -51.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net $0.00
YoY Change
Cash From Financing Activities -4.203M 1.786M 1.386M
YoY Change 36.02% 1067.32% -92.9%
NET CHANGE
Cash From Operating Activities -16.68M 13.76M 100.6M
Cash From Investing Activities 2.831M -20.23M -153.9M
Cash From Financing Activities -4.203M 1.786M 1.386M
Net Change In Cash -18.25M -4.679M -51.66M
YoY Change -33.99% -319.26% -77.94%
FREE CASH FLOW
Cash From Operating Activities -$16.68M $13.76M $100.6M
Capital Expenditures $749.0K $1.704M $4.104M
Free Cash Flow -$17.43M $12.06M $96.46M
YoY Change -166.17% -63.85% 73.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0728374
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
2100 Powell Street
CY2023 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 720
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Emeryville
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94608
CY2023 dei City Area Code
CityAreaCode
510
CY2023 dei Local Phone Number
LocalPhoneNumber
848-5100
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2023 dei Trading Symbol
TradingSymbol
DVAX
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001029142
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-34207
CY2023 dei Entity Registrant Name
EntityRegistrantName
Dynavax Technologies Corp
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
false
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
900000000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
130614772
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
San Francisco, California
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150279000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
592023000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
422391000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12313000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
40607000
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
145130000
CY2023Q4 us-gaap Other Receivables
OtherReceivables
3926000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
2385000
CY2023Q4 us-gaap Inventory Net
InventoryNet
53290000
CY2022Q4 us-gaap Inventory Net
InventoryNet
59446000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18995000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
85629000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
859120000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
916985000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37297000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37596000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
24287000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
25745000
CY2023Q4 us-gaap Goodwill
Goodwill
2067000
CY2022Q4 us-gaap Goodwill
Goodwill
2006000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
74325000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3518000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2108000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5438000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-930584000
CY2023Q4 us-gaap Assets
Assets
997096000
CY2022Q4 us-gaap Assets
Assets
985850000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5245000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3211000
CY2023Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2982000
CY2022Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
4775000
CY2023Q4 dvax Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
0
CY2022Q4 dvax Coalition For Epidemic Preparedness Innovations Accruals
CoalitionForEpidemicPreparednessInnovationsAccruals
107738000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
49448000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30719000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
4520000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3631000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
62195000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
150074000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2802000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3922000
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
222698000
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
221578000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29720000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32801000
CY2023Q4 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
60337000
CY2022Q4 dvax Cepi Accrual Long Term
CepiAccrualLongTerm
0
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
384000
CY2023Q4 us-gaap Liabilities
Liabilities
375024000
CY2022Q4 us-gaap Liabilities
Liabilities
404837000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
278000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
129530000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129530000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
127604000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127604000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
130000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
128000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1554634000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1510518000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
922000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4367000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-924195000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
622072000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
997096000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
985850000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
232284000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
722683000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
439442000
CY2023 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
50167000
CY2022 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
262153000
CY2021 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
173572000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54886000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46600000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32228000
CY2023 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
152946000
CY2022 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
131408000
CY2021 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
100156000
CY2023 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2022 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2021 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2023 dvax Bad Debt Expense
BadDebtExpense
12313000
CY2022 dvax Bad Debt Expense
BadDebtExpense
0
CY2021 dvax Bad Debt Expense
BadDebtExpense
0
CY2023 us-gaap Costs And Expenses
CostsAndExpenses
269312000
CY2022 us-gaap Costs And Expenses
CostsAndExpenses
439161000
CY2021 us-gaap Costs And Expenses
CostsAndExpenses
304956000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-37028000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
283522000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
134486000
CY2023 us-gaap Investment Income Interest
InvestmentIncomeInterest
31993000
CY2022 us-gaap Investment Income Interest
InvestmentIncomeInterest
7912000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
140000
CY2023 us-gaap Interest Expense
InterestExpense
6757000
CY2022 us-gaap Interest Expense
InterestExpense
6732000
CY2021 us-gaap Interest Expense
InterestExpense
11176000
CY2023 us-gaap Sublease Income
SubleaseIncome
7577000
CY2022 us-gaap Sublease Income
SubleaseIncome
7685000
CY2021 us-gaap Sublease Income
SubleaseIncome
7735000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5232000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
49354000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-152000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
111000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
294299000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
77521000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2022000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1143000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
808000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6389000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
293156000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
76713000
CY2023 dvax Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
0
CY2022 dvax Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
283000
CY2021 dvax Undistributed Earnings Allocated To Participating Securities
UndistributedEarningsAllocatedToParticipatingSecurities
4569000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6389000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
292873000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
72144000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
2.32
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.62
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.97
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.57
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128733000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126398000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116264000
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128733000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150797000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133006000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6389000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
293156000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
76713000
CY2023 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
2251000
CY2022 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-1407000
CY2021 dvax Change In Unrealized Gain On Marketable Securities Available For Sale
ChangeInUnrealizedGainOnMarketableSecuritiesAvailableForSale
-30000
CY2023 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1079000
CY2022 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1765000
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2509000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3330000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3172000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2539000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3059000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
289984000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
74174000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
58693000
CY2021 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
6684000
CY2021 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwards
-107000
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
841000
CY2021 dvax Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
59888000
CY2021 dvax Issuance Of Common Stock Net Of Issuance Costs In Conjunction With An Underwritten Public Offering And An At Market Sales Agreement
IssuanceOfCommonStockNetOfIssuanceCostsInConjunctionWithAnUnderwrittenPublicOfferingAndAnAtMarketSalesAgreement
28156000
CY2021 dvax Issuance Of Capped Call Options See Note10
IssuanceOfCappedCallOptionsSeeNote10
-27240000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21285000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2539000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
76713000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
222374000
CY2022 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
9640000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1430000
CY2022 dvax Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
24670000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
32915000
CY2022 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3172000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
293156000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
581013000
CY2023 dvax Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
6361000
CY2023 dvax Issuance Of Common Stock Upon Release Of Restricted Stock Awards Net Of Statutory Tax Withholdings
IssuanceOfCommonStockUponReleaseOfRestrictedStockAwardsNetOfStatutoryTaxWithholdings
-6370000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1535000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
42592000
CY2023 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3330000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6389000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
622072000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6389000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
293156000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
76713000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4342000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3812000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4296000
CY2023 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2934000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2856000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2762000
CY2023 us-gaap Inventory Write Down
InventoryWriteDown
0
CY2022 us-gaap Inventory Write Down
InventoryWriteDown
34288000
CY2021 us-gaap Inventory Write Down
InventoryWriteDown
2588000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
16555000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
4181000
CY2021 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-470000
CY2023 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5232000
CY2023 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1801000
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
49354000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
42592000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
32915000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
21285000
CY2023 dvax Non Cash Interest Expense
NonCashInterestExpense
1120000
CY2022 dvax Non Cash Interest Expense
NonCashInterestExpense
1088000
CY2021 dvax Non Cash Interest Expense
NonCashInterestExpense
1608000
CY2023 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2022 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2021 us-gaap Gains Losses On Sales Of Assets
GainsLossesOnSalesOfAssets
1000000
CY2023 dvax Bad Debt Expense
BadDebtExpense
12313000
CY2022 dvax Bad Debt Expense
BadDebtExpense
0
CY2021 dvax Bad Debt Expense
BadDebtExpense
0
CY2023 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-43268000
CY2022 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
15699000
CY2021 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
109155000
CY2023 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-3909000
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
32399000
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
234000
CY2023 dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
-0
CY2022 dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
-159655000
CY2021 dvax Increase Decrease In Prepaid Manufacturing
IncreaseDecreaseInPrepaidManufacturing
130232000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4673000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11865000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
64558000
CY2023 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-570000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-87000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-175000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1952000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
691000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-767000
CY2023 dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
0
CY2022 dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
-21110000
CY2021 dvax Increase Decrease In Cepi Accrual
IncreaseDecreaseInCepiAccrual
128848000
CY2023 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
3629000
CY2022 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
3125000
CY2021 dvax Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
3234000
CY2023 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-349864000
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
311652000
CY2023 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
19809000
CY2022 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-24788000
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
39725000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
100563000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
62716000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
335528000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
636921000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
632306000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
164928000
CY2023 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
486097000
CY2022 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
322450000
CY2021 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
187630000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
4104000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7139000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9477000
CY2023 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1000000
CY2022 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1000000
CY2021 us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1000000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-153928000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-315995000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14225000
CY2023 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
28156000
CY2023 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2022 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
CY2021 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
219822000
CY2023 dvax Payments For Purchase Of Capped Call Options
PaymentsForPurchaseOfCappedCallOptions
0
CY2022 dvax Payments For Purchase Of Capped Call Options
PaymentsForPurchaseOfCappedCallOptions
0
CY2021 dvax Payments For Purchase Of Capped Call Options
PaymentsForPurchaseOfCappedCallOptions
27240000
CY2023 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2022 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
190194000
CY2023 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8455000
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
17814000
CY2023 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
6360000
CY2022 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
9639000
CY2021 dvax Proceeds From Exercise Of Stock Options And Restricted Stock Awards Net
ProceedsFromExerciseOfStockOptionsAndRestrictedStockAwardsNet
6577000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1535000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
1431000
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
841000
CY2023 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
6509000
CY2022 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
0
CY2021 dvax Payments For Taxes Related To Net Share Settlement Of Rsus
PaymentsForTaxesRelatedToNetShareSettlementOfRsus
0
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1386000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19525000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
55776000
CY2023 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
324000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-443000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1431000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-51655000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-234197000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
404098000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
32310000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2023 us-gaap Income Taxes Paid
IncomeTaxesPaid
2014000
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
2208000
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
1312000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
5638000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
5638000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
9815000
CY2023 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
71307000
CY2022 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
0
CY2021 dvax Reclassification Of Contract Asset From Other Current Assets To Other Assets
ReclassificationOfContractAssetFromOtherCurrentAssetsToOtherAssets
0
CY2023 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
-60337000
CY2022 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
0
CY2021 dvax Reclassification Of Cepi Accrual To Cepi Accrual Long Term
ReclassificationOfCepiAccrualToCepiAccrualLongTerm
0
CY2023Q4 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
-47401000
CY2022Q4 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
0
CY2021Q4 dvax Advance Payment From Customer
AdvancePaymentFromCustomer
0
CY2023 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
299000
CY2022 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1015000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
591000
CY2023 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1332000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2848000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2468000
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Management’s estimates are based on historical information available as of the date of the consolidated financial statements and various other assumptions we believe are reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. Changes in estimates are reflected in reported results in the period in which they become known.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
CY2023 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
1100000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-1800000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-2500000
CY2023 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
-100000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
100000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
900000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Concentration of Credit Risk and Other Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our policy is to invest cash in institutional money market funds and marketable securities of the U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds, U.S. treasuries, U.S. government agency securities and corporate debt securities. We have not experienced any significant losses on our cash equivalents and marketable securities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our accounts receivable balance consists, primarily, of amounts due from product sales. Accounts receivable are recorded net of reserves for chargebacks, distribution fees, trade discounts and doubtful accounts. We estimate our allowance for doubtful accounts based on</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">an evaluation of the aging of our receivables. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. During the year ended December 31, 2023, we recorded an allowance for doubtful accounts of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">12.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> million, which was determined by assessing changes in </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Biological E. Limited's (“Bio E”) credit risk, contemplation of ongoing negotiations relating to Bio E Amendment No. 3 (See Note 9), and Bio E's dependence on cash collections from the Government of India, which have been delayed and significantly reduced in connection with the overall reduction in demand for CORBEVAX from the Government of India. As of December 31, 2023 and 2022</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">three</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">customers collectively represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">81</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">78</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our HEPLISAV-B trade receivable balance, respectively. As of December 31, 2023, we had no CpG 1018 adjuvant trade receivable balance. As of December 31, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2022, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">one</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> customer represented approximately </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our CpG 1018 adjuvant trade receivable balance</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our product candidates will require approval from the United States Food and Drug Administration ("FDA") and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our product candidates will receive any of these required approvals. The denial or delay of such approvals may have a material adverse impact on our business and may impact our business in the future. In addition, after the approval of HEPLISAV-B by the FDA, there is still an ongoing risk of adverse events that did not appear during the drug approval process that could affect our authorizations in the future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of product candidates, product liability, the volatility of our stock price and the need to obtain additional financing.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Our long-lived assets located in the United States as of December 31, 2023 and 2022, represented </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">31</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">% of our total assets, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">respectively, and the remaining long-lived assets were located in Germany.</span></p>
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12300000
CY2023Q4 dvax Percentage Of Long Lived Assets
PercentageOfLongLivedAssets
0.31
CY2022Q4 dvax Percentage Of Long Lived Assets
PercentageOfLongLivedAssets
0.34
CY2023 dvax Inventory Write Offs Recognized
InventoryWriteOffsRecognized
34300000
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
440131000
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
150279000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202004000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
436189000
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
277000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
207000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
219000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
150556000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
202211000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
436408000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
440104000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
151046000
CY2022Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
4720000
CY2023Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2467000
CY2022Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
2464000
CY2023Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
37201000
CY2022Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
28822000
CY2023Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
5822000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
151919000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
591177000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
592023000
CY2023 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2022 us-gaap Debt Securities Available For Sale Realized Loss
DebtSecuritiesAvailableForSaleRealizedLoss
0
CY2023Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
27256000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
25517000
CY2023Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18954000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
23934000
CY2023Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
7080000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
9995000
CY2023Q4 us-gaap Inventory Net
InventoryNet
53290000
CY2022Q4 us-gaap Inventory Net
InventoryNet
59446000
CY2023Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
15752000
CY2022Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
15139000
CY2023Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
2827000
CY2022Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
2360000
CY2023Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
5060000
CY2022Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
11613000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
69129000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
65118000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
31832000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
27522000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37297000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
37596000
CY2023 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4300000
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3800000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
4300000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
17069000
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
14261000
CY2023Q4 dvax Revenue Reserve Accrual Current
RevenueReserveAccrualCurrent
21004000
CY2022Q4 dvax Revenue Reserve Accrual Current
RevenueReserveAccrualCurrent
10552000
CY2023Q4 dvax Accrued Inventory
AccruedInventory
4456000
CY2022Q4 dvax Accrued Inventory
AccruedInventory
2209000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
6919000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3697000
CY2023Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
49448000
CY2022Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
30719000
CY2023 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2031-03-31
CY2023 us-gaap Lessee Operating Sublease Option To Extend
LesseeOperatingSubleaseOptionToExtend
The subtenant has no option to extend the sublease term.
CY2023 us-gaap Sublease Income
SubleaseIncome
7600000
CY2022 us-gaap Sublease Income
SubleaseIncome
7700000
CY2021 us-gaap Sublease Income
SubleaseIncome
7700000
CY2023Q4 dvax Percentage Of Excess Rent Paid To Landlord
PercentageOfExcessRentPaidToLandlord
0.50
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
6215000
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
5563000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
6222000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
6265000
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
7200000
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
6800000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
7000000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4496000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3631000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
29720000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32801000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
34216000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
36432000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Next Twelve Months
LessorSubleaseRentalsPaymentsToBeReceivedNextTwelveMonths
5684000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
7605000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Two
LessorSubleaseRentalsPaymentsToBeReceivedDueYearTwo
5854000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
6980000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Three
LessorSubleaseRentalsPaymentsToBeReceivedDueYearThree
6030000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
6122000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Four
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFour
6211000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
6052000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Year Five
LessorSubleaseRentalsPaymentsToBeReceivedDueYearFive
6397000
CY2023 us-gaap Debt Instrument Convertible Threshold Trading Days
DebtInstrumentConvertibleThresholdTradingDays
20
CY2023Q4 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
330100000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Due Thereafter
LessorSubleaseRentalsPaymentsToBeReceivedDueThereafter
15103000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
15062000
CY2023Q4 dvax Lessor Sublease Rentals Payments To Be Received Due
LessorSubleaseRentalsPaymentsToBeReceivedDue
45279000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
48036000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
13820000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
34216000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y7M6D
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.101
CY2023Q4 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
18866000
CY2023Q4 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
11983000
CY2023Q4 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
12516000
CY2023Q4 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0
CY2023Q4 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0
CY2023Q4 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0
CY2023Q4 us-gaap Purchase Obligation
PurchaseObligation
43365000
CY2023 dvax Description Of Avecia Supply Agreement
DescriptionOfAveciaSupplyAgreement
On September 7, 2023 (the “Effective Date”), we entered into an agreement (the “Avecia Supply Agreement”) with Nitto Denko Avecia Inc. (“Avecia”) for the manufacture and supply of our CpG 1018 adjuvant using a specific production process. Under the Avecia Supply Agreement, Avecia has agreed to produce and supply to us quantities of CpG 1018 adjuvant ordered by us after the Effective Date. Subject to certain conditions in the Avecia Supply Agreement, we are obligated to purchase all of our annual volume requirements of CpG 1018 adjuvant from Avecia up to a specified production capacity. We may alternatively order CpG 1018 adjuvant produced using a different production process pursuant to the existing supply agreement between us and Avecia dated October 1, 2012 (the “2012 Agreement”). As of December 31, 2023, our aggregate minimum commitment for the supply of CpG 1018 adjuvant under the Avecia Supply Agreement was $7.4 million within the next 12 months. As of December 31, 2022, we had no non-cancelable purchase and other commitments for the supply of CpG 1018 adjuvant.
CY2023Q4 dvax Aggregate Minimum Commitment
AggregateMinimumCommitment
7400000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12300000
CY2023Q2 dvax Prepayment Of Advance Payment
PrepaymentOfAdvancePayment
13500000
CY2023Q2 dvax Repayment Of Advance From Customer
RepaymentOfAdvanceFromCustomer
47400000
CY2023Q3 us-gaap Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Modification Of Contract
ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
33700000
CY2023 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5636000
CY2022 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5638000
CY2023 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1121000
CY2022 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
1094000
CY2023 us-gaap Interest Expense Debt
InterestExpenseDebt
6757000
CY2022 us-gaap Interest Expense Debt
InterestExpenseDebt
6732000
CY2023 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
232284000
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
722683000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
439442000
CY2023 us-gaap Contract With Customer Asset Change In Method Credit Loss Expense Reversal
ContractWithCustomerAssetChangeInMethodCreditLossExpenseReversal
71307000
CY2023Q4 us-gaap Contract With Customer Asset Accumulated Allowance For Credit Loss Noncurrent
ContractWithCustomerAssetAccumulatedAllowanceForCreditLossNoncurrent
71307000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-6389000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
293156000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
76713000
CY2022 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-283000
CY2021 us-gaap Undistributed Earnings Loss Allocated To Participating Securities Basic
UndistributedEarningsLossAllocatedToParticipatingSecuritiesBasic
-4569000
CY2023 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6389000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
292873000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
72144000
CY2023 dvax Addition Of Undistributed Earnings Allocated To Series B And Warrants
AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
0
CY2022 dvax Addition Of Undistributed Earnings Allocated To Series B And Warrants
AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
283000
CY2021 dvax Addition Of Undistributed Earnings Allocated To Series B And Warrants
AdditionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
4569000
CY2023 dvax Deduction Of Undistributed Earnings Allocated To Series B And Warrants
DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
0
CY2022 dvax Deduction Of Undistributed Earnings Allocated To Series B And Warrants
DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
0
CY2021 dvax Deduction Of Undistributed Earnings Allocated To Series B And Warrants
DeductionOfUndistributedEarningsAllocatedToSeriesBAndWarrants
-4190000
CY2023 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
0
CY2022 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
5044000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
16291000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1982000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.17
CY2023 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
850000
CY2021 us-gaap Interest Expense Medium Term Notes
InterestExpenseMediumTermNotes
3168000
CY2023 dvax Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
-0
CY2022 dvax Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
-1801000
CY2021 dvax Fair Value Adjustments Of Warrants
FairValueAdjustmentsOfWarrants
0
CY2023 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-6389000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
296399000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
75691000
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128733000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126398000
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
116264000
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2774000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3075000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21543000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13667000
CY2023 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2022 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
82000
CY2021 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128733000
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
150797000
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133006000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
129530228
CY2022Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
15000000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9339000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.7
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y7M9D
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
7.48
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
90000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
10.93
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
261000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
21.39
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10120000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.78
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y2M4D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37388000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9976000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
10.77
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P4Y1M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
37024000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7014000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.4
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y6M
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
29613000
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
42592000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32915000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21285000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
42592000
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
32915000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21285000
CY2021Q2 dvax Increase In Number Of Employee Stock Purchase Plan Shares Authorized For Issuance
IncreaseInNumberOfEmployeeStockPurchasePlanSharesAuthorizedForIssuance
1000000
CY2023 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
1300000
CY2022 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
900000
CY2021 us-gaap Defined Benefit Plan Contributions By Employer
DefinedBenefitPlanContributionsByEmployer
300000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-6275000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
292460000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
75954000
CY2023 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1908000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1839000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
1567000
CY2023 dvax Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
-4367000
CY2022 dvax Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
294299000
CY2021 dvax Income Loss From Continuing Operations Before Income Taxes
IncomeLossFromContinuingOperationsBeforeIncomeTaxes
77521000
CY2023 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-178000
CY2022 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
-165000
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
345000
CY2023 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1533000
CY2022 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
897000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
260000
CY2023 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
667000
CY2022 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
411000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
203000
CY2023 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2022000
CY2022 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
1143000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
808000
CY2023 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2023 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2022000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1143000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
808000
CY2023 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-917000
CY2022 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
61775000
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
16397000
CY2023 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
574000
CY2022 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2942000
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
3576000
CY2023 dvax Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
2050000
CY2022 dvax Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
3246000
CY2021 dvax Income Tax Reconciliation Tax Credit
IncomeTaxReconciliationTaxCredit
982000
CY2023 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
334000
CY2022 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
586000
CY2021 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
424000
CY2023 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
830000
CY2022 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
-473000
CY2021 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
131000
CY2023 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1466000
CY2022 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-324000
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-86847000
CY2023 dvax Section162 M Limitation
Section162MLimitation
1963000
CY2022 dvax Section162 M Limitation
Section162MLimitation
1779000
CY2021 dvax Section162 M Limitation
Section162MLimitation
1241000
CY2023 dvax Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
0
CY2022 dvax Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
-378000
CY2021 dvax Income Tax Rate Reconciliation Mark To Market Of Warrants
IncomeTaxRateReconciliationMarkToMarketOfWarrants
10364000
CY2023 dvax Net Operating Loss And Tax Credit Limitations
NetOperatingLossAndTaxCreditLimitations
0
CY2022 dvax Net Operating Loss And Tax Credit Limitations
NetOperatingLossAndTaxCreditLimitations
-56908000
CY2021 dvax Net Operating Loss And Tax Credit Limitations
NetOperatingLossAndTaxCreditLimitations
56459000
CY2023 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-518000
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
879000
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-290000
CY2023 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
340000
CY2022 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
395000
CY2021 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
335000
CY2023 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2022000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1143000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
808000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
96336000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
113228000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
34940000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
33444000
CY2023Q4 dvax Deferredtaxassetsoperatinglosscarryforwardscapitalization
Deferredtaxassetsoperatinglosscarryforwardscapitalization
22556000
CY2022Q4 dvax Deferredtaxassetsoperatinglosscarryforwardscapitalization
Deferredtaxassetsoperatinglosscarryforwardscapitalization
15308000
CY2023Q4 dvax Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
8868000
CY2022Q4 dvax Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
9530000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
10572000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation
7780000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
15808000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
9089000
CY2023Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
348000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
337000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
189428000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
188716000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
180387000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
178920000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9041000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
9796000
CY2023Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2667000
CY2022Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
2916000
CY2023Q4 dvax Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
6345000
CY2022Q4 dvax Deferred Tax Liabilities Operating Lease Right Of Use Assets
DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets
6785000
CY2023Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
29000
CY2022Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
95000
CY2023Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
9041000
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
9796000
CY2023Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2022Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
1500000
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
300000
CY2023Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
353500000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12100000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11300000
CY2023Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11339000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
5615000
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
762000
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
670000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
0
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
5054000
CY2023 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2022 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
0
CY2023 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Settlements With Taxing Authorities
UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
0
CY2022 us-gaap Unrecognized Tax Benefits Reductions Resulting From Lapse Of Applicable Statute Of Limitations
UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
0
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12101000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
11339000
CY2023 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0

Files In Submission

Name View Source Status
0000950170-24-018766-index-headers.html Edgar Link pending
0000950170-24-018766-index.html Edgar Link pending
0000950170-24-018766.txt Edgar Link pending
0000950170-24-018766-xbrl.zip Edgar Link pending
dvax-20231231.htm Edgar Link pending
dvax-20231231.xsd Edgar Link pending
dvax-ex21_1.htm Edgar Link pending
dvax-ex23_1.htm Edgar Link pending
dvax-ex31_1.htm Edgar Link pending
dvax-ex31_2.htm Edgar Link pending
dvax-ex32_1.htm Edgar Link pending
dvax-ex32_2.htm Edgar Link pending
dvax-ex97_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img25882306_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
dvax-20231231_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable